Literature DB >> 15789152

Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Elinor Langfelder-Schwind1, Edward Kloza, Elaine Sugarman, Barbara Pettersen, Trisha Brown, Kim Jensen, Seth Marcus, Joy Redman.   

Abstract

For over a decade, prenatal screening for cystic fibrosis (CF) has been considered a model for the integration of genetic testing into routine medical practice. Data from pilot studies and public policy discourse have led to recommendations by some professional organizations that CF screening should be offered or made available to pregnant women and their partners, and to couples planning a pregnancy. It is crucial that genetic counselors gain thorough understanding of the complexities of CF and the implications of positive test results, so that they may serve as a reliable, educated referral base and resource for health care providers and their patients. While not all pregnant women will be referred for genetic counseling prior to CF carrier testing, genetic counselors often will be asked to counsel clients after they have a positive test result, or who are found to be at increased risk. Genetic counselors can play an important role in providing accurate and current information as well as support for patients' informed decisions. These recommendations were created by a multicenter working group of genetic counselors with expertise in CF and are based on personal clinical experience, review of pertinent English language medical articles, and reports of expert committees. The recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. These recommendations do not displace a health care provider's professional judgment based on the clinical circumstances of a particular client.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15789152     DOI: 10.1007/s10897-005-1496-5

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  78 in total

1.  Cystic fibrosis carrier population screening in the primary care setting.

Authors:  S Loader; P Caldwell; A Kozyra; J C Levenkron; C D Boehm; H H Kazazian; P T Rowley
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  The American Society of Human Genetics statement on cystic fibrosis screening.

Authors:  C T Caskey; M M Kaback; A L Beaudet
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

3.  CFTR gene variant IVS8-5T in disseminated bronchiectasis.

Authors:  P F Pignatti; C Bombieri; M Benetazzo; A Casartelli; E Trabetti; L S Gilè; L C Martinati; A L Boner; M Luisetti
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

4.  Cystic fibrosis in Finland: a molecular and genealogical study.

Authors:  J Kere; R Norio; E Savilahti; X Estivill; A de la Chapelle
Journal:  Hum Genet       Date:  1989-08       Impact factor: 4.132

5.  Carrier screening for cystic fibrosis: costs and clinical outcomes.

Authors:  D A Asch; J C Hershey; M L Dekay; M V Pauly; J P Patton; M K Jedrziewski; F Frei; R Giardine; J A Kant; M T Mennuti
Journal:  Med Decis Making       Date:  1998 Apr-Jun       Impact factor: 2.583

6.  A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis.

Authors:  A M Vintzileos; C V Ananth; J C Smulian; A J Fisher; D Day-Salvatore; T Beazoglou
Journal:  Obstet Gynecol       Date:  1998-04       Impact factor: 7.661

7.  Couple-based prenatal screening for cystic fibrosis in primary care settings.

Authors:  R A Doherty; G E Palomaki; E M Kloza; J L Erickson; J E Haddow
Journal:  Prenat Diagn       Date:  1996-05       Impact factor: 3.050

8.  Correlation between genotype and phenotype in patients with cystic fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

9.  Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization.

Authors:  E S Tambor; B A Bernhardt; G A Chase; R R Faden; G Geller; K J Hofman; N A Holtzman
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

10.  Cascade carrier-testing in cystic fibrosis.

Authors:  Theresa Roberts; Martin J Schwarz; Rowan Kerr-Liddell; Joanna L Hinks; Maurice Super
Journal:  Paediatr Respir Rev       Date:  2003-12       Impact factor: 2.726

View more
  6 in total

1.  Personal genomics services: whose genomes?

Authors:  David Gurwitz; Yael Bregman-Eschet
Journal:  Eur J Hum Genet       Date:  2009-03-04       Impact factor: 4.246

2.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

3.  The changing landscape of carrier screening: expanding technology and options?.

Authors:  Michelle L McGowan; Deborah Cho; Richard R Sharp
Journal:  Health Matrix Clevel       Date:  2013

4.  Web Platform vs In-Person Genetic Counselor for Return of Carrier Results From Exome Sequencing: A Randomized Clinical Trial.

Authors:  Barbara B Biesecker; Katie L Lewis; Kendall L Umstead; Jennifer J Johnston; Erin Turbitt; Kristen P Fishler; John H Patton; Ilana M Miller; Alexis R Heidlebaugh; Leslie G Biesecker
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

5.  Presenting life with cystic fibrosis: a Q-methodological approach to developing balanced, experience-based prenatal screening information.

Authors:  Katherine F Wright; Louise D Bryant; Stephen Morley; Jenny Hewison; Alistair J A Duff; Daniel Peckham
Journal:  Health Expect       Date:  2013-08-02       Impact factor: 3.377

6.  Genetic dissection of diabetes: facing the giant.

Authors:  David Meyre; Guillaume Pare
Journal:  Diabetes       Date:  2013-10       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.